Schrodinger, INC Form 4 insider transactions

Rachit Jain, EVP & CFO of Schrodinger, Inc., sold 875 shares of common stock on July 16, 2026 for $15.60 per share.

Richard Friesner, a Director at Schrodinger, Inc., reported transactions involving the transfer of common stock from a grantor retained annuity trust to a family trust and direct ownership.

Schrodinger, Inc. President and CEO Ramy Farid exercised stock options and sold shares under a pre-established 10b5-1 plan.

EVP & CFO Rachit Jain sold 844 shares of Schrodinger, Inc. to cover tax withholding obligations related to RSU vesting.

Schrodinger's Chief Accounting Officer, Jenny Herman, sold common stock to cover tax liabilities from RSU vesting, not as a discretionary trade.

Schrodinger's EVP & CFO, Rachit Jain, reported a planned sale of 1,631 common shares to cover tax liabilities from RSU vesting, executed under a Rule 10b5-1 plan.

Schrodinger's EVP, CLO & CPO, Yvonne Tran, sold 1,094 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Schrodinger, Inc. President and CEO Ramy Farid reported a non-discretionary sale of 3,661 common shares to cover tax liabilities from RSU vesting.

Schrodinger's President of Therapeutics R&D sold 1,366 shares to cover tax liabilities from RSU vesting.

Kenneth Patrick Lorton, EVP, CTO & COO of Software at Schrodinger, Inc., sold 1,222 shares of common stock to cover tax liabilities from RSU vesting.

Schrodinger's EVP, Chief Scientific Officer, Robert Lorne Abel, sold 1,300 shares of common stock to cover tax obligations from RSU vesting.

Schrodinger's EVP, CLO & CPO, Yvonne Tran, sold 776 shares of common stock to cover tax liabilities from RSU vesting, as per a pre-arranged 10b5-1 plan.

Schrodinger's EVP, CTO & COO, Software, Kenneth Patrick Lorton, sold 925 shares of common stock to cover tax liabilities from RSU vesting.

Schrodinger's Chief Accounting Officer, Jenny Herman, sold 752 shares of common stock to cover tax liabilities from RSU vesting.

Schrodinger's EVP and Chief Scientific Officer, Robert Lorne Abel, sold 1,230 shares of common stock to cover tax liabilities from RSU vesting.

Schrodinger's Chief Medical Officer, Margaret Dugan, sold 1,395 shares of common stock to cover tax liabilities from RSU vesting under a Rule 10b5-1 plan.

Schrodinger, Inc. Director Jeffrey Chodakewitz was granted 5,997 restricted stock units and 9,341 stock options as part of his compensation, aligning his interests with shareholder value.

Schrodinger, Inc. Director Gary Sender was granted 5,997 restricted stock units and options to purchase 9,341 shares of common stock, vesting over one year, as part of the company's 2022 Equity Incentive Plan.

Schrodinger, Inc. Director Michael Lynton was granted 5,997 restricted stock units and 9,341 stock options as part of his compensation, aligning his interests with shareholders.

Schrodinger, Inc. Director Bridget van Kralingen was granted 1,499 restricted stock units and 2,335 stock options, aligning her compensation with long-term shareholder interests.

Schrodinger, Inc. Director Nancy Thornberry was granted 5,997 restricted stock units and options to purchase 9,341 shares of common stock as part of her compensation.

Schrodinger, Inc. Director Rosana Kapeller-Libermann was granted 5,997 restricted stock units and options to purchase 9,341 shares of common stock on June 18, 2025, as part of the company's 2022 Equity Incentive Plan.

Schrodinger, Inc. Director Gary L. Ginsberg was granted 5,997 Restricted Stock Units (RSUs) and options to purchase 9,341 shares of common stock, aligning his interests with shareholders.

Schrodinger, Inc. Director Arun Oberoi was granted 5,997 Restricted Stock Units and options to purchase 9,341 shares of common stock, aligning his interests with the company's long-term performance.

Schrodinger, Inc. Director Richard Friesner was granted 5,997 Restricted Stock Units and 9,341 stock options, aligning his interests with the company's long-term performance.

Mannix Vartan Aklian, EVP and Chief Commercial Officer of Schrodinger, Inc., was granted 14,063 restricted stock units and options to purchase 84,375 shares of common stock as part of an inducement equity incentive plan.

Rachit Jain, EVP & CFO of Schrodinger, Inc., reports the acquisition of restricted stock units and stock options.

Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Bridget A van Kralingen reports the acquisition of stock options and restricted stock units in Schrodinger, Inc.

Jenny Herman, SVP & Controller of Schrodinger, Inc., sold 666 shares of common stock on March 6, 2025, to cover withholding tax obligations related to vesting restricted stock units.